GlaxoSmithKline PLC Annual Report 2020 on Form 20-F (1804S)
2021年3月15日 - 04:00PM
RNSを含む英国規制内ニュース (英語)
TIDMGSK
RNS Number : 1804S
GlaxoSmithKline PLC
12 March 2021
GlaxoSmithKline plc
Annual Report 2020 on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange
Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that
on 12 March 2021 it filed with the Securities and Exchange
Commission an Annual Report on Form 20-F that included audited
financial statements for the year ended 31 December 2020. GSK's
2020 Annual Report on Form 20-F is available online at GSK's
website at www.gsk.com/corporatereporting and also online at
www.sec.gov .
Ordinary Shareholders may also elect to receive notification by
email of the publication of financial reports by registering on
www.shareview.co.uk .
A hard copy version of the GSK 2020 Annual Report, together with
the Notice of Annual General Meeting will be available on or about
30 March 2021.
Shareholders have the ability to receive, upon request, a hard
copy version of GSK's complete audited financial statements for the
year ended 31 December 2020, free of charge, by either:
(i) writing to Equiniti Limited, our registrars in the UK, at
the following address: Equiniti Limited, Aspect House, Spencer
Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384
2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);
(ii) writing to J.P. Morgan Chase Bank, N.A. our ADR depositary
in the US, at the following address: EQ Shareowner Services, P.O.
Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 800 990
1135 (US toll free) or +1 651 453 2128 (outside the US); or
(iii) contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).
Victoria Whyte
Company Secretary
12 March 2021
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2020.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSJTMMTMTTBTJB
(END) Dow Jones Newswires
March 15, 2021 03:00 ET (07:00 GMT)
Gsk (LSE:GSK)
過去 株価チャート
から 2 2024 まで 3 2024
Gsk (LSE:GSK)
過去 株価チャート
から 3 2023 まで 3 2024